On Monday, in the course of current trade, Shares of JPMorgan Chase & Co. (NYSE:JPM), climbed 0.90%, and is now trading at $68.66.
JPMorgan Chase & Co., released its latest Retirement Insights paper outlining best practices for selecting a target date strategy for defined contribution plans (DC). The white paper, “Custom or off-the-shelf target date strategies?,” explores several factors – such as asset allocation, administration selection and fee structure – that DC plan sponsors and financial advisors should carefully consider when deciding whether a custom or “off-the-shelf” target date strategy is most appropriate for their plan. Key findings comprise:
- Choosing between custom or off-the-shelf target date strategies requires extensive analysis. Plan sponsors and financial advisors need to balance the benefits that custom strategies might offer with the required expertise, time and costs, which can be significant.
- Custom target date strategies can be precisely designed to meet specific plan requirements. These strategies can take into account employee demographics and particular plan design features (for example, a prohibition against plan loans or pre-retirement withdrawals).
- In a custom strategy, a plan sponsor can consolidate investment managers from defined benefit plans to potentially achieve economies of scale and realize savings on overall fees. But a substantial asset base (greater than $500 million) may be needed to secure those savings. Smaller plans will likely be better served by an off-the-shelf target date strategy.
- Effective communications are critical when implementing a custom strategy. While participants in an off-the-shelf target date strategy can access relevant information about their strategy’s funds on fund company websites, participants in a custom strategy may have only one source of information about their retirement funds: the communications they receive from their plan sponsor.
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
During an Afternoon trade, Shares of Equity Commonwealth (NYSE:EQC), climbed 0.41%, and is now trading at $27.16.
Equity Commonwealth, stated financial results for the quarter ended June 30, 2015. All per share results are stated on a fully diluted basis.
Results for the quarter ended June 30, 2015
Funds from Operations (FFO), as defined by the National Association of Real Estate Investment Trusts, for the quarter ended June 30, 2015 were $77.2 million, or $0.59 per share. This compares to FFO for the quarter ended June 30, 2014 of $87.1 million, or $0.70 per share.
Normalized FFO was $67.8 million, or $0.52 per share. This compares to Normalized FFO for the quarter ended June 30, 2014 of $81.3 million, or $0.66 per share. The following items influenced Normalized FFO per share for the quarter ended June 30, 2015 contrast to the corresponding 2014 period:
- about ($0.13) per share from properties sold;
- about ($0.11) per share due to the sale of the company’s entire interest in Select Income REIT (SIR) in 2014;
- about $0.08 per share from lower interest expense; and
- about $0.06 per share from lower general & administrative (G&A) expense, not taking into account shareholder litigation and transition expenses.
Equity Commonwealth (EQC) is an internally managed and self-advised real estate investment trust (REIT). The Company is engaged in the ownership and operation primarily of office buildings in central business district (CBD) and suburban locations throughout the United States.
Finally, Juno Therapeutics Inc (NASDAQ:JUNO), gained 0.50% Monday.
Juno Therapeutics, will declare financial results for the second quarter of 2015 on Wednesday, August 12, 2015 after the close of U.S.-based financial markets. Following the declarement, Juno administration will host a conference call and live webcast to provide a business update and talk about financial results startning at 2:00 p.m. Pacific Time (PT)/5:00 p.m. Eastern Time (ET).
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
